• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

What Is The Upside of Establishing Extended Reality As A Medical Device?

by Eran Orr, Founder of XRHealth 07/31/2019 Leave a Comment

Extended Reality (XR) as a Medical Device




Eran Orr, Founder of XRHealth

XR stands for extended reality. Basically, it’s an umbrella term covering the VR (virtual reality), AR (augmented reality), and MR (mixed reality) technologies. All three are already involved or will be involved in healthcare. In the very near future, you will be able to “swipe” between all three within an application. Different combinations of the technologies will be used to provide specific health benefits, eventually all within a single platform.

It is sometimes hard to explain to people that are not from the VR, AR or MR industry what XR is, why it’s needed and what it can provide in terms of healthcare benefits. There are uses for pain relief, support for people with autism, surgical training, telementoring, and even patient education. There are XR applications for motor function, cognitive decline, pain management, and hot flashes.

It is certainly possible to build and market singular XR applications for each of these benefits. Another approach is to build a single platform that will answer the needs of the VR believers in the healthcare market and not just try to target one specific use case. Then clinicians will basically be using XR like a tool kit with the ability to pick and choose the different apps inside a platform according to the specific use case or the specific needs of a patient.

To achieve the goal of an all-purpose tool kit, the establishment of XR platforms as medical devices is a sound strategy and would certainly elevate this nascent industry. However, it is far more complex to be a medical device company than to be “just” an XR company. Organizations that choose this route have to work within the confines of the one acronym that matters in the United States, the FDA (Food and Drug Administration). In particular, it is the FDA’s Center for Devices and Radiological Health (CDRH) that is in charge of reviewing medical device applications. The more complicated the device, the higher level of scrutiny is applied.  

What is the upside of establishing extended reality as a medical device?

It is about being able to make scientific claims about the device, its intended use and proven outcomes (as demonstrated by clinical trials). It comes from being able to provide data measuring patient performance which scientifically establishes that VR can treat a patient, with similar or even better outcomes in order to become a replacement for some of the drugs that are on the market today, as an example. The downside is that it takes time to establish, document and provide quality assurance for the procedures that “create” the device, followed by clinical trials and the ultimate documentation of results. 

Operating as a medical device company also can chew up 30-40 percent of your overhead. Even sales reps need to be a “medical device certified” sales rep because they just can’t promise things that are not aligned with a device’s claims or intended use. The whole effort is broader than just R&D. Strict adherence to procedures applies in marketing, in sales, and in everything that a medical device company is doing.

Establishing extended reality as medical device is a complicated business hurdle and one that many VR companies may not choose to undertake. But the decision to become a medical device company pays off because it forces you to become rigorous and structured. Especially within healthcare, it provides a cache of acceptance because a regulatory body has passed judgment in the overarching realm of safety and effectiveness. And for healthcare, as far as reimbursement goes, operating as a medical device company, means that approved devices get assigned to the medical billing and coding system (CPT codes) for a particular procedure. Being in “the system” is quite helpful in the clinician billing process. And it allows companies to build applications that fit the current CPT codes. 

All this being said, it is important to understand that the FDA is not a barrier to entry in the XR space. As a regulatory body, they believe in fostering cooperation because they understand that the potential of digital health is enormous. Like everything else, as long as you are playing according to the rules and not doing things that are not allowed, the FDA is very open-minded for new technologies. They also understand that it is a necessity to have new technologies in the market for the advancement of healthcare.

XR/VR companies are beginning to realize that gaming and social entertainment are not the only markets available for innovation. The need for XR advancement in healthcare is obvious. Thanks to the regulatory review process, eventually you will see XR in every hospital and every rehab center. More than likely, the first encounter that anyone will have with XR will be in such a controlled environment, a facility where your clinician is with you making sure you know how to use the technology. Once deemed safe and effective by the FDA, you’ll be able to take an XR headset back home and a clinician will be able to do everything remotely, including monitoring.

XR is poised to become the next telehealth platform, to be used for diagnostics and for treatment. However, achieving such lofty status will require rigorous scientific study. And the market itself still needs the public to become fully educated. But the momentum is there. The positive patient reaction, provider reaction, and payer reaction to XR healthcare devices that we are seeing today is only the beginning.

About Eran Orr

Eran Orr is the founder of XRHealth, a first-of-its-kind healthcare technology company that helps clinicians better manage their patients’ healthcare via specialized extended reality (XR) technology solutions and data analysis. He also serves as the CEO of XRHealth USA Inc., based in Boston, MA. Eran has since established himself as a worldwide leader in the XR and health industries.

Tagged With: Augmented Reality, Autism, Clinical Trials, digital health, Extended Reality (XR), FDA, healthcare technology, Medical Billing, Medical Device, Medical Devices, Mixed Reality, Pain Management, Patient Education, Tele, telehealth, Virtual Reality, XRHealth

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |